Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:59-63. doi: 10.1007/s00228-013-1487-7. Epub 2013 May 3.
Access to medicines filling children's therapeutic needs is a long-standing global problem. The problem has been recognised and initiatives for correction were adopted in the USA in the late 1990s, and in the European Union in the first decade of this century. Paediatric medicines are particularly problematic in middle- and low-income countries, where most of the children of the world live.
A paediatric medicines initiative involving the WHO in parallel with the US and EU initiatives was seen as important by the global paediatric and paediatric clinical pharmacology community, but the WHO was resistant to getting involved.
Advocacy, networking, cooperation, persistence, hard work and some luck were needed to get the "Better medicines for children" resolution 60.20 adopted by the World Health Assembly in May 2007.
Science has been a key enabler of the developments leading to and following the adoption of the paediatric initiatives, but as the example of the WHO shows, science alone was not enough to make the change.
满足儿童治疗需求的药物供应是一个长期存在的全球性问题。该问题在美国上世纪 90 年代末和欧盟本世纪初得到了认识,并采取了相应的纠正措施。在中低收入国家,儿科药物特别成问题,因为这些国家生活着世界上大多数儿童。
全球儿科和儿科临床药理学界认为,与美国和欧盟举措同时涉及世界卫生组织(WHO)的儿科药物举措很重要,但世卫组织对此持抵制态度。
经过大力倡导、建立网络、合作、坚持不懈、辛勤工作和一些运气,最终在 2007 年 5 月获得世界卫生大会通过了第 60.20 号“改善儿童药物”决议。
科学是推动儿科举措的发展及其后续工作的关键因素,但正如世卫组织的例子所表明的,仅仅依靠科学是不足以实现变革的。